Overview

Casopitant (Oral) And ZOFRAN To Prevent Postoperative Nausea And Vomiting In Women

Status:
Completed
Trial end date:
2006-07-01
Target enrollment:
Participant gender:
Summary
This study is being conducted to see if adding GW679769 (casopitant) to ZOFRAN will significantly decrease the number of patients who experience nausea and vomiting after surgery.
Phase:
Phase 3
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Casopitant
Neurokinin-1 Receptor Antagonists